Results 241 to 250 of about 4,652,143 (319)

Endothelial Elavl1 Is Required for CD8 T-Cell Persistence in Atherosclerosis. [PDF]

Arterioscler Thromb Vasc Biol
Nicholas SE, Helming SB, Ménoret A, Pathoulas CL, Xu MM, Hensel J, Kimble AL, Heineman B, Jellison ER, Reese B, Zhou B, Rodriguez-Oquendo A, Vella AT, Murphy PA.   +13 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Portrayed the development of activated T cell to exhausted T cell based on the ratio of CD28 to CTLA4. [PDF]

Cancer Immunol Immunother
Wang Y, Mei X, Zhong J, Wang J, Cao J, Zheng S, Qi D, Wang Z.   +7 more
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

γδ T cell-derived IL-4 initiates CD8⁺ T cell immunity. [PDF]

Nat Immunol
Le S, Dooley N, Murphy D, Liu S, Gandolfo LC, Ge Z, May R, Cozijnsen A, Burn TN, Jennison C, Bachem A, Xu C, Koay HF, Schröder J, Oyong D, Nalubega M, Kenangalem E, Gras S, Cockburn IA, Bedoui S, Mackay LK, McFadden GI, Fernandez-Ruiz D, Boyle M, Heath WR, Beattie L.   +25 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Aberrant IL-21/STAT3 signaling disrupts regulatory T cell function and CD4⁺ T cell homeostasis in children with type 1 diabetes. [PDF]

Front Immunol
Sun X, Zhao J, Liu J, Zhou W.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Landscape of T-cell engagers in solid tumors. [PDF]

Oncologist
Garcia-Lorenzo E, Dorta M, Doger B, Pedregal M, Moreno V.   +4 more
europepmc   +1 more source